<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Novavax Inc (NASDAQ: NVAX) said that its two-dose COVID-19 vaccine was 80% overall effective against COVID-19 in a late-stage trial testing the shot in teens aged 12 to 17 years. The trial involved 2,247 adolescents between May and September 2021, when the Delta variant was the dominant strain in the U.S.
...read full article on Benzinga
